Poor Survival With COVID in Patients Who Have Had HSCT Poor Survival With COVID in Patients Who Have Had HSCT

Patients who developed COVID-19 within 12 months of receiving a hematopoetic stem cell transplant (HSCT) were especially vulnerable.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news